Abstract
Brad Lewis, MD, of Machaon Diagnostics, discusses the implications of three recent studies on acquired hemophilia, thrombotic thrombocytopenic purpura (TTP), and hereditary hemorrhagic telangiectasia (HHT). A small trial on acquired hemophilia found that emicizumab reduced mortality, while a TTP study suggested that silent cerebral infarctions could be a marker for stroke risk and treatment aims. Finally, a trial on VAD044 for HHT showed promising results in reducing epistaxis and improving hemoglobin levels, marking the potential for the first dedicated therapy for this commonly overlooked bleeding disorder.
Visit https://jadpro.com/videos/meeting-highlights/ for short videos about these important abstracts.
